Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4863376
Max Phase: Preclinical
Molecular Formula: C11H7FN2
Molecular Weight: 186.19
Molecule Type: Unknown
Associated Items:
ID: ALA4863376
Max Phase: Preclinical
Molecular Formula: C11H7FN2
Molecular Weight: 186.19
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Fc1ccc2[nH]c3ccncc3c2c1
Standard InChI: InChI=1S/C11H7FN2/c12-7-1-2-10-8(5-7)9-6-13-4-3-11(9)14-10/h1-6,14H
Standard InChI Key: XDMDASHVJGGFLB-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 186.19 | Molecular Weight (Monoisotopic): 186.0593 | AlogP: 2.86 | #Rotatable Bonds: 0 |
Polar Surface Area: 28.68 | Molecular Species: BASE | HBA: 1 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 2 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 13.17 | CX Basic pKa: 8.69 | CX LogP: 2.02 | CX LogD: 1.18 |
Aromatic Rings: 3 | Heavy Atoms: 14 | QED Weighted: 0.57 | Np Likeness Score: -0.95 |
1. Schwarthoff S, Tischer N, Sager H, Schätz B, Rohrbach MM, Raztsou I, Robaa D, Gaube F, Arndt HD, Winckler T.. (2021) Evaluation of γ-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors., 46 [PMID:34391122] [10.1016/j.bmc.2021.116355] |
Source(1):